JP2024531234A5 - - Google Patents

Info

Publication number
JP2024531234A5
JP2024531234A5 JP2024508656A JP2024508656A JP2024531234A5 JP 2024531234 A5 JP2024531234 A5 JP 2024531234A5 JP 2024508656 A JP2024508656 A JP 2024508656A JP 2024508656 A JP2024508656 A JP 2024508656A JP 2024531234 A5 JP2024531234 A5 JP 2024531234A5
Authority
JP
Japan
Prior art keywords
cells
modified
primary
hla
islet cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074878 external-priority patent/WO2023019229A1/en
Publication of JP2024531234A publication Critical patent/JP2024531234A/ja
Publication of JP2024531234A5 publication Critical patent/JP2024531234A5/ja
Pending legal-status Critical Current

Links

JP2024508656A 2021-08-11 2022-08-11 同種異系細胞療法のための遺伝子改変された初代細胞 Pending JP2024531234A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163232161P 2021-08-11 2021-08-11
US63/232,161 2021-08-11
US202263297694P 2022-01-07 2022-01-07
US63/297,694 2022-01-07
US202263344502P 2022-05-20 2022-05-20
US63/344,502 2022-05-20
US202263348990P 2022-06-03 2022-06-03
US63/348,990 2022-06-03
US202263353531P 2022-06-17 2022-06-17
US63/353,531 2022-06-17
PCT/US2022/074878 WO2023019229A1 (en) 2021-08-11 2022-08-11 Genetically modified primary cells for allogeneic cell therapy

Publications (2)

Publication Number Publication Date
JP2024531234A JP2024531234A (ja) 2024-08-29
JP2024531234A5 true JP2024531234A5 (cg-RX-API-DMAC7.html) 2025-08-18

Family

ID=83692683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508656A Pending JP2024531234A (ja) 2021-08-11 2022-08-11 同種異系細胞療法のための遺伝子改変された初代細胞

Country Status (9)

Country Link
US (1) US20240010988A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384189A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024531234A (cg-RX-API-DMAC7.html)
KR (1) KR20240073006A (cg-RX-API-DMAC7.html)
AU (1) AU2022325232A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227108A1 (cg-RX-API-DMAC7.html)
IL (1) IL310691A (cg-RX-API-DMAC7.html)
MX (1) MX2024001208A (cg-RX-API-DMAC7.html)
WO (1) WO2023019229A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173737A1 (en) * 2021-02-09 2022-08-18 Millennium Pharmaceuticals, Inc. Methods and compositions for freezing and thawing mammalian cells
CN121843705A (zh) * 2023-05-03 2026-04-10 萨那生物科技公司 工程化胰岛细胞的给药和施用方法
WO2025047921A1 (ja) * 2023-09-01 2025-03-06 株式会社セル―ジョン 拒絶反応に対する回避方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
WO1998041641A1 (en) 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
ES2299417T3 (es) * 2000-04-12 2008-06-01 Beta-Cell N.V. Metodo para producir preparaciones de celulas endocrinas pancreaticas madura e inmaduras, preparacion de las celulas y su utilizacion para el tratamiento de la diabetes mellitus.
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7355012B2 (en) 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ATE418346T1 (de) 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
GB201212902D0 (en) 2012-07-20 2012-09-05 Univ Singapore Combinatoric encoding methods for microarrays
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP3243831A1 (en) 2014-02-27 2017-11-15 Ucl Business Plc Variants of the proliferation-inducing ligand (april)
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
US20160017288A1 (en) * 2014-05-28 2016-01-21 Eitan Moshe Akirav Method for inducing the formation of islet structures and improving beta cell function
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
BR112017020750A2 (en) 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US20180291080A1 (en) 2015-09-28 2018-10-11 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
EP3858388B1 (en) 2015-09-28 2024-07-03 Regents of the University of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
KR20240095477A (ko) 2017-01-13 2024-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
AU2018269194B2 (en) 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
CN111328290A (zh) 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
EP3728576A4 (en) 2017-12-22 2021-11-24 The Broad Institute, Inc. CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES
US20230193242A1 (en) 2017-12-22 2023-06-22 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
WO2019126762A2 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
AU2019305585A1 (en) * 2018-07-17 2021-01-28 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells
EP3824075A4 (en) 2018-07-17 2022-04-20 The Regents of The University of California CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP7853210B2 (ja) 2020-01-13 2026-04-28 サナ バイオテクノロジー,インコーポレイテッド 血液型抗原の修飾
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CA3193099A1 (en) 2020-09-24 2022-03-31 David R. Liu Prime editing guide rnas, compositions thereof, and methods of using the same

Similar Documents

Publication Publication Date Title
Finck et al. Engineered cellular immunotherapies in cancer and beyond
Li et al. Emerging trends in clinical allogeneic CAR cell therapy
JP7372920B2 (ja) Car t細胞の作製を改良するための方法
JP7837068B2 (ja) ユニバーサル抗原提示細胞およびその使用
DE60026166T2 (de) Vetozellen die wirksam in der prävention von transplantatabstossung sind und kein graft-versus-host potential aufweisen
JP2018188475A (ja) カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP2025504392A5 (cg-RX-API-DMAC7.html)
Su et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies
JP2024525789A (ja) 細胞ベースの療法のためのポリシストロニックベクター
US20210268023A1 (en) Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection
EP4175651A1 (en) Methods and compositions for editing the b2m locus in b cells
US20230279352A1 (en) Methods for generating primary immune cells
CA3249498A1 (en) ALLOGENIC T LYMPHOCYTES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
Gea-Banacloche Immunomodulation
Tatum et al. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors
JP5054875B2 (ja) 樹状細胞ハイブリッドによって活性化される細胞傷害性tリンパ球
Lotz et al. Partial tyrosinase‐specific self tolerance by HLA‐A* 0201‐restricted cytotoxic T lymphocytes in mice and man
Agrawal et al. Vaccine and cell-based therapeutic approaches in acute myeloid leukemia
JP7856563B2 (ja) がんのt細胞治療のための細胞傷害性エフェクターメモリーt細胞の産生方法
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
EP3958887B1 (en) Medical uses for inducing or restoring immune tolerance
US20240374722A1 (en) T cell product and use thereof
CN118451181A (zh) 工程化用于基于细胞的疗法的细胞以及相关组合物和方法
WO2026059868A2 (en) Immunosuppression resistant t cells for post-transplant disorders
CN117957327A (zh) 用于基于细胞的疗法的多顺反子载体